Here, we used an in vivo/in vitro approach to test the hypothesis that inhibition of NADPH oxidase reduces microglia-mediated neuropathology (neuroinflammation, oxidative stress, and neuron damage) and behavioral symptoms (learning and memory deficits) associated with AD. Here, FMO5 is linked to Alzheimer disease.